Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

EP: 1.Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP: 2.Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP: 3.Recurrence and BCG Resistance in High-Risk NMIBC

EP: 4.Therapies Beyond BCG: FDA-Approved and Emerging Options

EP: 5.Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

EP: 6.CORE-001 Trial Participation and Eligibility Criteria

EP: 7.Comparing Cretostimogene and BCG Administration Methods

EP: 8.Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

EP: 9.Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

EP: 10.Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

EP: 11.Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

Now Viewing

EP: 12.Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Video content above is prompted by the following questions:

• What are your thoughts regarding cretostimogene as monotherapy versus a combination therapy? Could you comment on how you would use this in your clinical practice either as a monotherapy or combination therapy and which patients may benefit from either approach?
• Why is it important that urologists stay informed about advances in managing BCG-unresponsive NMIBC now that we have multiple therapeutic agents approved in this disease state?
• Please share any closing thoughts regarding the unmet needs that remain in the management of BCG-unresponsive NMIBC, along with the impact cretostimogene plus pembrolizumab combination therapy could have on the overall care of patients with NMIBC.